Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 16/20 | 0.74 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.74 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.74 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.74 |
| ▸ | SRC | P12931 | 5/20 | 0.53 |
| ▸ | EGFR | P00533 | 4/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.53 |
| ▸ | PRKCG | P05129 | 1/20 | 0.53 |
| ▸ | PRKCB | P05771 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | PRKCH | P24723 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.53 |
| ▸ | WEE1 | P30291 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927322 | 0.84 | FGFR1 (0.57) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL14011443 | 0.84 | RIPK2 (0.69) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL12908056 | 0.81 | FGFR1 (0.55) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL928109 | 0.80 | FGFR1 (0.68) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL927380 | 0.79 | FGFR1 (0.53) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL12943335 | 0.79 | FGFR1 (0.52) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL927776 | 0.79 | FGFR1 (0.53) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL928330 | 0.77 | FGFR1 (0.67) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL927658 | 0.76 | FGFR1 (0.49) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL928985 | 0.76 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | claimed |
| EP-2099797-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-09-29 | — | — | EP | claimed |
| EP-2099797-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2009-09-16 | — | — | EP | claimed |
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-12-04 | — | — | US | claimed |
| WO-2007021795-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | claimed |
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | disclosed |
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | disclosed |
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | disclosed |
| EP-2099797-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-09-29 | — | — | EP | disclosed |
| EP-2099797-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2009-09-16 | — | — | EP | disclosed |
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-12-04 | — | — | US | disclosed |
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-12-04 | — | — | US | disclosed |
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-12-04 | — | — | US | disclosed |
| WO-2007021795-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021795-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | SGK2, BRSK2, FYN | FGFR1 239/4885FGFR2 167/4885FGFR4 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.